Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2009. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of £12.19 per Ordinary share at the time of the transaction.
Material Changes
The filing details changes in share interests for five individuals arising from the purchase of Ordinary shares on November 4, 2009. These purchases resulted from the reinvestment of dividends on shares held within an Individual Savings Account (ISA). The specific changes in share counts are as follows:
- Mr A P Witty: 13 shares
- Mr J S Heslop: 7 shares
- Mr S M Bicknell: 49 shares
- Mr E J Gray: 6 shares
- Mr D S Redfern: 6 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: November 4, 2009.
- Transaction Type: Dividend reinvestment within an ISA.
- Share Price: £12.19 per Ordinary share.
- Notification Date: November 5, 2009.
- Regulatory Basis: Disclosure and Transparency Rule 3.1.4R(1)(a).